Eckert & Ziegler To Supply Ablaze Pharmaceuticals With Lutetium-177 For Clinical Trials

Eckert & Ziegler and Ablaze Pharmaceuticals (Ablaze) signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a. 177Lu). Eckert & Ziegler will serve as the supplier for Ablaze’s clinical trial and research activities utilizing Lutetium-177.

Ablaze is currently developing several Lutetium-based drug products for targeted radiotherapy (TRT). In the TRT approach, a radioisotope such as lutetium-177 is combined with tumor-specific drugs, which then deliver the radiating element of the radioisotope into tumor cells to destroy them, while largely sparing surrounding healthy tissue.

"We are excited to support the development of Ablaze’s innovative radiopharmaceuticals by providing our high-quality Lutetium-177,” stated Jutta Ludwig, Member of the Executive Board of Eckert & Ziegler and responsible for the Asia Business. “With this agreement, we are further strengthening our position on the Chinese market. Starting with clinical trial supply, we jointly aim to establish a long-term collaboration that includes supply for commercial products as well as future developments.”

"Our goal to improve the availability of TRT products in China and to make them accessible to Chinese patients requires strong and reliable partners,” said Dr Alex Qiao, Co-Founder, President and CEO of Ablaze. "We are excited about the partnership with an expert like Eckert & Ziegler who is able to guarantee the quality and security of supply we need to drive our activities forward.”

Apart from Lutetium-177, Eckert & Ziegler supplies international pharmaceutical companies with Gallium-68, Yttrium-90, Actinium-225 and other radioisotopes that are crucial for use in diagnostics and therapy.